Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.66 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.66 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12979545 | 0.92 | NR1H2 (0.66) | RXRANR1H2NR1H3PTGS2HSD17B1 | |
| SCHEMBL3472821 | 0.89 | RXRA (0.63) | RXRANR1H2NR1H3PTGS2HSD17B1 | |
| SCHEMBL16452704 | 0.88 | NR1H2 (0.51) | RXRANR1H2NR1H3HSD17B1HSD17B2 | |
| SCHEMBL15230208 | 0.88 | NR1H2 (0.61) | RXRANR1H2NR1H3PTGS2HSD17B1 | |
| SCHEMBL16455488 | 0.87 | RXRA (0.51) | RXRANR1H2NR1H3PTGS2HSP90AA1 | |
| SCHEMBL16455318 | 0.87 | NR1H2 (0.60) | RXRANR1H2NR1H3PTGS2HSD17B1 | |
| SCHEMBL3472326 | 0.87 | RXRA (0.60) | RXRANR1H2NR1H3PTGS2HSD17B1 | |
| SCHEMBL15242996 | 0.87 | NR1H2 (0.60) | RXRANR1H2NR1H3PTGS2HSD17B1 | |
| SCHEMBL3472975 | 0.87 | RXRA (0.67) | RXRANR1H2NR1H3PTGS2HSD17B1 | |
| SCHEMBL15229773 | 0.86 | NR1H2 (0.58) | RXRANR1H2NR1H3PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101895-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS, INC. | 2021-04-08 | — | — | US | disclosed |
| EP-3441390-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | Ralexar Therapeutics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-2820013-B9 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS INC (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2820013-B1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS INC (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9637481-B2 | Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions | RALEXAR THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150152094-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-8987318-B2 | Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions | ALEXAR THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150045399-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. (US) | 2015-02-12 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2013130892-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | ANAYADERM, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| CN-101248048-B | Imidazole based LXR modulators | EXELIXIS INC | 2013-08-28 | — | — | CN | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| CN-101248048-A | Imidazole based LXR modulators | EXELIXIS INC (US) | 2008-08-20 | — | — | CN | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045399-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | RXRA 3/4885NR1H2 1/4885NR1H3 2/4885 |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | RXRA 3/4885NR1H2 1/4885NR1H3 2/4885 |
| US-20210101895-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | NR1H2, NR1H3, RXRG | RXRA 4/4885NR1H2 1/4885NR1H3 2/4885 |
| US-20150152094-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | NR1H2, NR1H3, RXRA | RXRA 3/4885NR1H2 1/4885NR1H3 2/4885 |
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | RXRA 18/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.